Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
**Background:** Atrial fibrillation (AF) affects approximately 350,000 Canadians and has an estimated annual economic burden exceeding $800 million dollars. Anti-arrhythmic drug (AAD) therapy and catheter ablation (CA) are the two common treatments for paroxysmal AF. However, the upfront costs of CA...
Saved in:
Main Authors: | Yaariv Khaykin, Peter J. Mallow, John A. Rizzo, Atul Verma, Lauren Chun, Shelby Olesovsky, Matthew R. Reynolds |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2016-10-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9837 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
by: Matthew R. Reynolds, et al.
Published: (2014-10-01) -
Machine Learning in the Management of Patients Undergoing Catheter Ablation for Atrial Fibrillation: Scoping Review
by: Aijing Luo, et al.
Published: (2025-02-01) -
Left atrial strain predicts paroxysmal atrial fibrillation recurrence after catheter ablation: a 1-year study using three-dimensional speckle-tracking echocardiography
by: Rui Zhang, et al.
Published: (2025-02-01) -
Comparative safety and effectiveness of cryoballoon versus radiofrequency ablation for atrial fibrillation: a systematic review and meta-analysis
by: Muhammad Furqan, et al.
Published: (2025-02-01) -
Cryoballoon ablation for atrial fibrillation in South Africa: One-year outcome from the Cryo Global Registry
by: A Stanley, et al.
Published: (2024-03-01)